Drugs / ADSC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06843122 | Mar 2025 → Feb 2027 expected | ulcer of lower limbs | Medical University of Warsaw | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06843122 ↗ |
| Known as | ASC | “ADSC/ASC will be administered twice, at two-week intervals - during V0 and V2 visits” NCT06843122 ↗ |
| Modality | Cell therapy | “allogenic mesenchymal stem cells isolated from adipose tissue” NCT06843122 ↗ |